Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan Kabi is indicated for colorectal malignancies and is incorporated into established chemotherapy protocols.

• Colorectal cancer (first‑line): combined with fluorouracil and leucovorin to increase tumor response and improve resection rates.
• Metastatic colorectal cancer (second‑line): administered after progression on first‑line therapy to extend progression‑free survival.
• Colorectal cancer (adjuvant): given post‑surgery to reduce the risk of disease recurrence in high‑risk patients.
• Advanced colorectal cancer (palliative): used to alleviate symptoms and control tumor growth.

• Irinotecan is a pro‑drug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the enzyme‑DNA cleavable complex, SN‑38 prevents relegation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately tumor cell apoptosis. Its activity is enhanced in tumors with low expression of the metabolizing enzyme UGT1A1, which can affect drug clearance.

Irinotecan Kabi may cause a spectrum of adverse reactions, ranging from common, manageable events to serious, potentially life‑threatening conditions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset that may require antiemetic therapy.
• Diarrhea: frequent loose stools often occurring early in treatment.
• Fatigue: generalized tiredness affecting daily activities.
• Neutropenia: reduced white blood cell count increasing infection susceptibility.

Serious or Rare Side Effects

• Severe neutropenia with fever: risk of life‑threatening infection requiring hospitalization.
• Severe diarrhea (colitis): can lead to dehydration, electrolyte imbalance, and may need intensive care.
• Allergic reactions: anaphylaxis or severe hypersensitivity requiring immediate medical intervention.

When prescribing Irinotecan Kabi, clinicians should observe several precautionary measures to ensure patient safety.

• Monitor blood counts: perform regular CBC to detect neutropenia early.
• Assess liver function: adjust therapy in patients with hepatic impairment.
• Evaluate renal function: consider dose modification for renal insufficiency.
• Avoid concurrent strong CYP3A4 inhibitors: may increase irinotecan exposure and toxicity.
• Educate patients on early signs of diarrhea and infection: prompt reporting is essential.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Kabi can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may raise irinotecan plasma levels.
• UGT1A1 inhibitors (e.g., atazanavir): increase risk of severe neutropenia and diarrhea.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): monitor INR for bleeding risk.
• Other myelosuppressive agents: increase risk of bone‑marrow suppression.
• Antidiarrheal agents (loperamide) used excessively: may mask severity of irinotecan‑induced diarrhea.